A Clinical Study Finds Pfizer's Dacomitinib Delays The Growth of Lung Cancer Cells Better Than AstraZeneca's Iressa Medicine & Technology Jun 06, 2017 In the last day of ASCO 2017 annual meeting on Tuesday, researchers presented the data of Dacomitinib that delayed the growth of the lung cancer longer than Gefitinib, trademarked as Iressa in newly diagnosed patients.
TECH & INNOVATION OpenAI’s Whisper Faces Scrutiny Over Accuracy, Experts Find 'Hallucinated' Text in Transcripts